
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Vonoprazan–tetracycline dual regimen as rescue therapy for *Helicobacter pylori* infection: randomized controlled trial  </title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">
<div class="mindmap">
<details><summary><strong>Vonoprazan–tetracycline dual regimen as rescue therapy for <em>Helicobacter pylori</em> infection: randomized controlled trial  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Source: Gastroenterology (pre‑proof), Accepted 6 Jan 2026, DOI 10.1053/j.gastro.2026.01.008  </li>
<li style="margin-left: 0px;">Topic: Rescue eradication therapy for <em>H. pylori</em> after ≥1 prior failure  </li>
<li style="margin-left: 0px;">Authors: Gao W et al.  </li>
</ul>
<details><summary><strong>1. Study Design &amp; Population  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prospective, open‑label, non‑inferiority RCT; 1:1 randomization to VT dual therapy vs. bismuth quadruple therapy (BQT) for 14 days.  </li>
<li style="margin-left: 0px;">Inclusion: adults 18–80 y, confirmed <em>H. pylori</em> (13C‑UBT), ≥1 prior eradication failure.  </li>
<li style="margin-left: 0px;">Exclusion: recent antibiotics/PPI/bismuth (&lt;4 wks), severe organ disease, pregnancy/lactation, known drug hypersensitivity, concurrent trial participation, psychiatric conditions impairing compliance.  </li>
<li style="margin-left: 0px;">Randomization: computer‑generated block size 4; allocation concealed in opaque envelopes; investigators &amp; participants unblinded, outcome assessors (UBT technicians) blinded.  </li>
</ul>
</div></details>
<details><summary><strong>2. Interventions &amp; Dosing  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>VT dual therapy</strong>: vonoprazan 20 mg BID + tetracycline 500 mg TID (total tetracycline 1.5 g/day).  </li>
<li style="margin-left: 0px;"><strong>BQT</strong>: lansoprazole 30 mg BID + colloidal bismuth 150 mg TID + tetracycline 500 mg TID + metronidazole 400 mg TID (standard 14‑day regimen).  </li>
<li style="margin-left: 0px;">Administration timing: acid‑suppressor/bismuth ~30 min pre‑meal; antibiotics immediately post‑meal.  </li>
</ul>
</div></details>
<details><summary><strong>3. Outcomes &amp; Statistical Plan  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Primary endpoint</strong>: non‑inferiority of eradication rate (13C‑UBT at 8 weeks) between VT and BQT. Non‑inferiority margin = 10%; one‑sided α = 0.025; Bonferroni‐adjusted α per comparison = 0.0125; power = 80%.  </li>
<li style="margin-left: 0px;"><strong>Secondary endpoints</strong>: incidence &amp; severity of treatment‑emergent adverse events (TEAEs), medication adherence (≥80% doses).  </li>
<li style="margin-left: 0px;">Populations: ITT (all randomized, loss → failure), modified ITT (received ≥1 dose + UBT), PP (completed ≥80% meds + follow‑up).  </li>
<li style="margin-left: 0px;">Analyses: categorical variables – χ² or Fisher; continuous – t‑test or Wilcoxon; CI 95%; non‑inferiority tested with two‑sided tests for each population.  </li>
</ul>
</div></details>
<details><summary><strong>4. Baseline Characteristics (n=350)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Age mean ± SD: VT 48 ± 13.4 y (range 18–77); BQT 45.7 ± 12.1 y (18–73).  </li>
<li style="margin-left: 0px;">Sex M/F: VT 60/115; BQT 66/109.  </li>
<li style="margin-left: 0px;">BMI mean ± SD: both groups 23 ± ≈3.5 kg/m².  </li>
<li style="margin-left: 0px;">Penicillin allergy: VT 63 (36%); BQT 56 (32%).  </li>
<li style="margin-left: 0px;">Prior eradication attempts median IQR: VT 2 (1–3); BQT 2 (1–2).  </li>
<li style="margin-left: 0px;">No significant differences in smoking, alcohol use, comorbidities, endoscopic diagnoses, or concomitant medications (all p &gt; 0.05).  </li>
</ul>
</div></details>
<details><summary><strong>5. Efficacy Results  </strong></summary><div style="padding-left: 20px;">
<table border="1" cellspacing="0" cellpadding="4">
<thead><tr>
<th>Analysis</th>
<th>VT eradication % (n/N)</th>
<th>BQT eradication % (n/N)</th>
<th>Difference (VT‑BQT)</th>
<th>P for non‑inferiority</th>
</tr></thead>
<tbody>
<tr>
<td>ITT</td>
<td>88.0 % (154/175)</td>
<td>86.3 % (151/175)</td>
<td>+1.7 % (95 CI –5.9 to 9.3)</td>
<td>P=0.0005</td>
</tr>
<tr>
<td>mITT</td>
<td>90.6 % (154/170)</td>
<td>89.3 % (151/169)</td>
<td>+1.2 % (95 CI –5.7 to 8.2)</td>
<td>P=0.0003</td>
</tr>
<tr>
<td>PP</td>
<td>91.1 % (153/168)</td>
<td>92.2 % (141/153)</td>
<td>–1.1 % (95 CI –7.8 to 5.6)</td>
<td>P=0.002</td>
</tr>
</tbody>
</table>
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">No statistically significant differences across ITT, mITT, PP (P = 0.75, 0.84, 0.88 respectively).  </li>
<li style="margin-left: 0px;">Sub‑analysis by penicillin allergy: VT eradication 91.8 % (no allergy) vs. 88.3 % (allergy); BQT 89.4 % vs. 89.3%; differences not significant (p &gt; 0.5).  </li>
</ul>
</div></details>
<details><summary><strong>6. Safety &amp; Adherence  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">TEAEs overall: VT 10.9 % (19/175) vs. BQT 45.7 % (80/175); P &lt; 0.001.  </li>
<li style="margin-left: 0px;">Grade distribution (VT/BQT): Mild 13/54 (P = 0.000), Moderate 4/10 (NS), Severe 2/16 (P = 0.001).  </li>
<li style="margin-left: 0px;">Most frequent AEs (VT): nausea 3, constipation 5, dizziness 2; (BQT): nausea 37, diarrhea 12, abdominal pain 9, bitter taste 8.  </li>
<li style="margin-left: 0px;">Discontinuations due to AEs: VT 0 % vs. BQT 8.6 % (15/175); P &lt; 0.001.  </li>
<li style="margin-left: 0px;">Adherence ≥80%: VT 96.0 % (168/175) vs. BQT 87.4 % (153/175); P = 0.006.  </li>
</ul>
</div></details>
<details><summary><strong>7. Limitations Highlighted by Authors  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Single‑center, open‑label design → potential reporting bias, limited external validity.  </li>
<li style="margin-left: 0px;">No individual <em>H. pylori</em> susceptibility testing; reliance on regional resistance data.  </li>
<li style="margin-left: 0px;">Non‑inferiority margin of 10 % considered relatively wide; stricter margins may be needed for definitive equivalence.  </li>
<li style="margin-left: 0px;">Sample size insufficient for stratified analysis by number of prior failures or specific prior regimens.  </li>
<li style="margin-left: 0px;">Gut microbiota impact not assessed; long‑term ecological effects unknown.  </li>
</ul>
</div></details>
<details><summary><strong>8. Discussion &amp; Interpretation  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT dual therapy <strong>met non‑inferiority</strong> criteria (P &lt; 0.01) despite a modestly lower absolute eradication rate in PP analysis (–1.1 %).  </li>
<li style="margin-left: 0px;">Simplified regimen <strong>removed bismuth and metronidazole</strong>, reducing pill burden from 8 tablets/day (BQT) to 5 tablets/day (VT).  </li>
<li style="margin-left: 0px;">Authors argue that potent acid suppression by vonoprazan (maintains gastric pH ≥6) <strong>enables a single low‑resistance antibiotic</strong> (tetracycline) to achieve reliable eradication.  </li>
</ul>
</div></details>
<details><summary><strong>9. Mechanistic Rationale &amp; Antibiotic Resistance Context  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Tetracycline resistance in Asia‑Pacific (1990–2022): <strong>~4 %</strong>, consistently lower than metronidazole (52 %), levofloxacin (26 %), clarithromycin (22 %).  </li>
<li style="margin-left: 0px;">Vonoprazan, a potassium‑competitive acid blocker, provides <strong>stronger and more sustained pH elevation</strong> than double‑dose PPIs, enhancing tetracycline activity.  </li>
<li style="margin-left: 0px;">No cross‑resistance reported between tetracycline and amoxicillin; VT may serve as an alternative for patients failing high‑dose amoxicillin dual therapy.  </li>
</ul>
</div></details>
<details><summary><strong>10. Subgroup &amp; Ancillary Analyses (Exploratory)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Prior regimen distribution (VT vs. BQT, n=175 each): Clarithromycin‑based ≈ 90 % in both groups; Levofloxacin‑based ~ 40 %; Metronidazole‑based ~ 50 %; Furozolidone‑based 10–14 %.  </li>
<li style="margin-left: 0px;">Patients with ≥2 prior failures: VT group 41.1 % vs. BQT 35.4 % (p = 0.07, not significant).  </li>
<li style="margin-left: 0px;">Early discontinuations (poor adherence) detailed in Table 3: VT 2 patients stopped (ages 34 M, 27 F); both had ≥80 % adherence before stop; one achieved eradication, the other failed. BQT 16 patients stopped early (various AEs), overall cure rate among them <strong>62.5 %</strong> (10/16).  </li>
</ul>
</div></details>
<details><summary><strong>11. Clinical Implications &amp; Recommendations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">VT dual therapy offers a <strong>penicillin‑free</strong>, simplified rescue option especially valuable for patients with documented penicillin allergy or intolerance to amoxicillin.  </li>
<li style="margin-left: 0px;">Lower adverse event profile and higher adherence suggest improved patient comfort and potential cost savings (fewer clinic visits, less need for supportive care).  </li>
<li style="margin-left: 0px;">Findings support the broader concept that <strong>potent acid suppression + a single low‑resistance antibiotic</strong> can replace complex quadruple regimens in rescue settings.  </li>
</ul>
</div></details>
<details><summary><strong>12. Future Research Directions (Authors’ Proposals)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Conduct <strong>multicenter, double‑blind trials</strong> with matched placebos to eliminate reporting bias and assess generalizability across diverse geographic resistance patterns.  </li>
<li style="margin-left: 0px;">Incorporate <strong>culture‑based susceptibility testing</strong> or molecular resistance profiling to correlate individual strain resistance with eradication outcomes.  </li>
<li style="margin-left: 0px;">Evaluate <strong>narrower non‑inferiority margins</strong> (e.g., 5 %) and larger sample sizes to confirm equivalence with high statistical rigor.  </li>
<li style="margin-left: 0px;">Perform <strong>stratified analyses</strong> by number of prior failures, specific previous regimens, and severity of gastric pathology (e.g., atrophic gastritis vs. ulcer disease).  </li>
<li style="margin-left: 0px;">Assess <strong>gut microbiota composition pre‑/post‑therapy</strong> to determine ecological impact of the simplified dual regimen versus BQT.  </li>
</ul>
</div></details>
<details><summary><strong>13. Key Take‑Home Messages (What You Need to Know)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;"><strong>Background</strong>: Rescue therapy traditionally relies on multi‑drug quadruple regimens that are hard to tolerate.  </li>
<li style="margin-left: 0px;"><strong>New Finding</strong>: VT dual therapy achieved eradication rates <strong>non‑inferior</strong> to BQT (≈90 % mITT) while causing <strong>~¾ fewer adverse events</strong> and yielding <strong>higher adherence</strong>.  </li>
<li style="margin-left: 0px;"><strong>Limitation</strong>: Open‑label, single‑center, no resistance testing → caution when extrapolating to regions with different tetracycline resistance patterns.  </li>
<li style="margin-left: 0px;"><strong>Clinical Relevance</strong>: VT dual therapy can be considered a practical alternative for patients struggling with pill burden or those with penicillin allergy; may also serve as a rescue option after amoxicillin‑based failures.  </li>
</ul>
</div></details>
<details><summary><strong>14. References (selected, clinically relevant)  </strong></summary><div style="padding-left: 20px;">
<p>1. Hooi JKY et al. Global prevalence of <em>H. pylori</em> infection. <strong>Gastroenterology</strong> 2017;153:420‑429.</p>
<p>2. Malfertheiner P et al. Maastricht VI/Florence consensus on <em>H. pylori</em> management. <strong>Gut</strong> 2022.</p>
<p>3. Liu L et al. Vonoprazan‑based vs. PPI‑based therapies meta‑analysis. <strong>Helicobacter</strong> 2024;29:e13094.</p>
<p>4. Gao W et al. Simplified VT dual therapy for penicillin‑allergic patients (first‑line). <strong>Gut</strong> 2024;73:1414‑1420.</p>
<p>5. Hong TC et al. Primary antibiotic resistance of <em>H. pylori</em> in Asia‑Pacific 1990‑2022. <strong>Lancet Gastroenterol Hepatol</strong> 2024;9:56‑67.</p>
<p><em>(All numbered references correspond to the original manuscript’s reference list; full citation details retained for traceability.)</em></p>
</div></details>
<details><summary><strong>15. Microbiological &amp; Pharmacologic Context  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Acid suppression intensity → gastric pH ≥6 critical for tetracycline activity; vonoprazan maintains higher intragastric pH than standard PPIs, explaining superior outcomes vs. omeprazole‑tetracycline dual therapy in earlier studies.  </li>
<li style="margin-left: 0px;">Tetracycline primary resistance in China <strong>&lt;4 %</strong> (regional data); stable even after multiple treatment failures → rationale for empiric use without susceptibility testing.  </li>
</ul>
</div></details>
<details><summary><strong>16. Trial Registration &amp; Transparency  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Registered at Chinese Clinical Trial Registry: ChiCTR2400080705, registration date 5 Feb 2024; protocol approved by Ethics Committee of Peking University First Hospital; conducted per Declaration of Helsinki.  </li>
<li style="margin-left: 0px;">Data not publicly available (privacy/ethical limits); obtainable from corresponding author with IRB approval.  </li>
</ul>
</div></details>
<details><summary><strong>17. Tables Summary (Key Data Extracted)  </strong></summary><div style="padding-left: 20px;">
<details><summary><strong>Table 1 – Demographics &amp; Clinical Variables (n=175/group)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Age, weight, BMI, smoking, alcohol, family gastric‑cancer history, penicillin allergy, endoscopic diagnosis, comorbidities: <strong>no significant inter‑group differences</strong> (all p &gt; 0.05).  </li>
</ul>
</div></details>
<details><summary><strong>Table 2 – Prior Eradication Regimens  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Median prior treatment times: VT 2 (IQR 1–3); BQT 2 (1–2) → p=0.052 (trend, not significant).  </li>
<li style="margin-left: 0px;">Prior regimen types distributed similarly across groups (clarithromycin‑based ≈ 90 %, levofloxacin‑based ~ 40 %, metronidazole‑based ~ 50 %).  </li>
</ul>
</div></details>
<details><summary><strong>Table 4 – Eradication Rates by Analysis Set  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">ITT: VT 88.0 % (154/175) vs. BQT 86.3 % (151/175); difference <strong>+1.7 %</strong>, non‑inferiority P=0.0005.  </li>
<li style="margin-left: 0px;">mITT: VT 90.6 % (154/170) vs. BQT 89.3 % (151/169); Δ 1.2 % (95 CI –5.7 to 8.2), non‑inferiority P=0.0003.  </li>
<li style="margin-left: 0px;">PP: VT 91.1 % (153/168) vs. BQT 92.2 % (141/153); Δ –1.1 % (95 CI –7.8 to 5.6), non‑inferiority P=0.002.  </li>
</ul>
</div></details>
<details><summary><strong>Table 6 – TEAEs Detail (Grade &amp; Specific Events)  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Total events VT 19/175 vs. BQT 80/175; <strong>P &lt; 0.001</strong>.  </li>
<li style="margin-left: 0px;">Mild AEs: nausea 3, constipation 5, dizziness 2 (VT); nausea 37, diarrhea 12, abdominal pain 9, bitter taste 8 (BQT).  </li>
<li style="margin-left: 0px;">Moderate‑to‑severe events VT 6 vs. BQT 26; <strong>P &lt; 0.001</strong>.  </li>
</ul>
</div></details>
</div></details>
<details><summary><strong>16. Author Conclusions &amp; Clinical Recommendations  </strong></summary><div style="padding-left: 20px;">
<ul style="list-style-type: disc;">
<li style="margin-left: 0px;">Fourteen‑day VT dual therapy is an <strong>effective</strong>, well‑tolerated rescue regimen for <em>H. pylori</em> after prior failure.  </li>
<li style="margin-left: 0px;">Eradication rates <strong>non‑inferior</strong> to standard BQT (difference ≤1.2 % across all analyses).  </li>
<li style="margin-left: 0px;">Simplified dosing <strong>substantially lowers adverse event burden</strong> (10.9 % vs. 45.7 %) and <strong>improves adherence</strong> (96 % vs. 87 %).  </li>
<li style="margin-left: 0px;">Authors suggest VT dual therapy be considered a <strong>practical, penicillin‑free alternative</strong>, especially for patients with documented amoxicillin intolerance or those unable to manage multi‑pill quadruple regimens.  </li>
</ul>
</div></details>
</div></details>
</div>
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
